10-Q quarterly report · filed Nov 5, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 10-Q Quarterly Report

Short answer

Amylyx Pharmaceuticals, Inc. (AMLX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$45M
−32.3% YoY · −4.8% QoQ
EPS (diluted)
−$0.39
−5.4% YoY · +0.0% QoQ

Source: XBRL data from the Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 10-Q on SEC EDGAR. USD.

Amylyx Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • No quarterly revenue, as Amylyx remained pre-commercial
  • Net loss $45.5M vs $34.4M YoY, operating margin not applicable
  • R&D $28.4M vs $19.9M, led by avexitide spending of $10.7M
  • Cash, equivalents and marketable securities $768.1M, boosted by $544.6M equity proceeds
  • Avexitide NDA submission targeted by end-2026, potential commercial launch in 2027 if approved

Risk Factors

  • Newly added regulatory risk: 2026 FDA draft guidance and policy reversals may make single-trial approval standards uncertain
  • Most materially updated regulatory risk: FDA leadership changes and personnel reductions could delay guidance, reviews, and approvals
  • Operational risk: rising GLP-1 demand could constrain peptide-manufacturing capacity and increase avexitide supply costs
  • Competitive risk: novel obesity treatments could reduce bariatric surgery and shrink the PBH patient population
  • Financial risk: accumulated deficit reached $881.6 million, with no committed source of additional capital

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Amylyx Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.